Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators designed this observational, retrospective, multicenter study including all patients who underwent surgery for non-colorectal liver metastases between January 2010 and December 2022, with the aim of establishing a series of recommendations for the treatment of liver metastases from various extrahepatic primary tumors
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with non-colorectal liver metastases | Patients who underwent liver resection for non-colorectal liver metastases from January 2010 to December 2022 |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival | Time from the date of liver resection for non-colorectal metastases to death from any cause. Survival will be assessed for up to 5 years postoperatively | 5 years from liver resection |
| Progression-Free Survival | Time from the date of liver resection for non-colorectal metastases to the date of documented disease progression or death from any cause, whichever occurs first. Patients without progression or death will be censored at the last follow-up | 5 years from surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Postoperative Morbidity Rate | Incidence of any postoperative complications occurring within 90 days after liver resection, including but not limited to infections, bleeding, bile leaks, and other surgical complications, classified according to standard criteria. | 90 days from surgery |
| Postoperative Mortality Rate |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients scheduled for liver surgery due to non-colorectal liver metastases, regardless of the primary tumor origin, via open or minimally invasive approach, from January 2010 to December 2022
The data will be shared with all investigators who have participated in this multicenter study and who have expressed interest in its follow-up and execution. The data will be shared anonymously, as each patient is assigned a unique anonymized identification number unrelated to their clinical records. Access to the data will be available for a period of five years following the end of recruitment, which was June 2025. There is no official repository; interested investigators must contact me directly, and I will provide them with unique and private access to the data
5 years following the end of recruitment, which was June 2025
All investigators who have participated in this multicenter study and who have expressed interest in its follow-up and execution.
Not provided
Not provided
Not provided
Not provided
Not provided
Proportion of patients who die from any cause within 90 days following liver resection surgery. |
| 90 days from surgery |
| Recurrence Pattern | Distribution and characterization of tumor recurrence (hepatic, extrahepatic, or both) after liver resection for non-colorectal metastases. | Up to 5 years from liver resection |
| Length of hospital stay | Number of days from surgery to discharge following liver resection | Perioperative/Periprocedural |
| R0 Resection Rate | Proportion of patients achieving complete microscopic liver tumor resection (R0) during liver resection | At surgery |